BriaCell just added a fourth active immunotherapy program to a pipeline that already has one candidate in Phase 3. The FDA didn’t blink. Two names covered here last week did get their answers this week, and the answers landed nothing alike, one company watched its stock double, the other is now talking about suing its own regulator.
BriaCell Receives FDA Clearance to Begin Bria-PROS+ Trial in Prostate Cancer
BriaCell Therapeutics (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced on August 5 that the FDA completed its review of the Investigational New Drug application for Bria-PROS+ and issued a Study May Proceed letter, clearing the company to begin a Phase 1/2a clinical study of the candidate in advanced prostate cancer. Bria-PROS+ is a personalized, off-the-shelf, cell-based immunotherapy built on HLA matching between the patient and the immunotherapy cell line, the same design principle behind BriaCell’s other personalized programs.
This is BriaCell’s fourth active clinical or soon-to-be-clinical immunotherapy program. Bria-IMT, its lead candidate, is already in a pivotal Phase 3 trial in metastatic breast cancer. Bria-OTS, an earlier personalized program, produced a sustained complete resolution of a lung metastasis in its first dosed patient. Bria-BRES+, a breast cancer program, received its own FDA clearance to begin clinical evaluation earlier this year. Bria-PROS+ was previously awarded a $2 million non-dilutive grant from the US National Cancer Institute to support its manufacturing and planned clinical evaluation, funding that does not dilute existing shareholders and was secured before this IND clearance.
The scientific case for Bria-PROS+ rests on preclinical data presented at the American Association for Cancer Research Annual Meeting, showing the candidate activates multiple arms of the immune system at once, naive T-cells, dendritic cells, and natural killer cells. BriaCell’s argument is that this multipronged activation could both improve efficacy and reduce the chance that tumors find a way around a single-mechanism attack, a pattern of immune escape that limits many single-target immunotherapies.
None of this is efficacy data in humans yet. A Study May Proceed letter clears the regulatory path to begin dosing patients; it says nothing about whether Bria-PROS+ will work. Personalized, HLA-matched cell therapy manufacturing is also inherently slower and more expensive to scale than an off-the-shelf small molecule, a real practical constraint as BriaCell now runs four programs in parallel. The company has not yet announced a timeline for first patient dosing in the new trial.
Replimune’s Panel Votes 10-3 in Favor of RP1, Reversing a Harsh FDA Briefing Document
Last week’s open question closed on July 30. Despite FDA staff briefing documents calling the supporting trial data “not interpretable” days before the meeting, Replimune’s (Nasdaq: REPL) advisory committee voted 10 to 3 that the IGNYTE study’s efficacy results are evaluable and clinically meaningful. The stock moved more than 100% higher on the news. RP1, combined with nivolumab, is Replimune’s third attempt at approval in advanced melanoma after two prior Complete Response Letters.
The underlying numbers: IGNYTE is a single-arm, open-label study of 340 patients, reporting a 33.6% objective response rate, a median duration of response of 24.8 months, and median overall survival of 32.9 months. Grade 3 or higher treatment-related side effects occurred in 31.4% of participants. Panel members who voted no cited the single-arm design itself, not the drug’s underlying value, as their concern; without a control group, isolating RP1’s contribution from nivolumab’s own activity is inherently harder to prove.
This vote is non-binding. The FDA’s Class 1 resubmission target action date is August 2, 2026, and the agency has diverged from advisory committee recommendations before, particularly around single-arm study design concerns like the ones raised here. A favorable vote after two CRLs is a meaningfully positive signal, not a guarantee.
Capricor CEO Won’t Rule Out Legal Action Against FDA Over Disputed Statistical Analysis Plan
Capricor’s (Nasdaq: CAPR) story from last week has taken a sharper turn. CEO Linda Marbán told BioSpace on July 31 she won’t rule out pursuing legal action against the FDA if the agency won’t find a path forward for deramiocel, alleging the agency’s use of an early, unsigned SAP draft version 1.1 as its primary benchmark reflected “ulterior motive” rather than standard review practice. An FDA spokesperson disputed that characterization, saying its review considered several SAP versions including the final version 3.0.
The timing added friction: The Lancet published the HOPE-3 trial data the same day as the adcomm, reporting that deramiocel slowed upper limb decline by 54% versus placebo, a result Capricor calls clinically meaningful. Oppenheimer analysts told investors they see no read-through from Capricor’s vote to other Duchenne muscular dystrophy names, including Sarepta, Precision BioSciences, Dyne Therapeutics, Satellos Bioscience, and Entrada Therapeutics, noting only Sarepta shares Capricor’s specific functional endpoint.
Capricor’s PDUFA date remains August 22. Marbán said the company is weighing whether to pursue a path forward with the FDA in the coming weeks or explore approval in Europe instead, a route she acknowledged has historically made re-entry to the US market difficult for other therapies. No legal filing has been made as of this writing.
Replimune’s FDA Decision, Capricor’s Next Move, and BriaCell’s Trial Launch to Watch
Replimune’s FDA decision on RP1 was due August 2, immediately following the favorable advisory vote; the outcome should be confirmed by the time this article is read. Capricor has until its August 22 PDUFA date to determine whether a path forward with the FDA exists before deciding on legal action or an EU-first strategy. BriaCell has not yet disclosed a timeline for dosing the first patient in the Bria-PROS+ Phase 1/2a study.
Sources
- BriaCell Therapeutics / BioSpace: BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer, August 5, 2026
- BioPharma Dive: Replimune melanoma drug wins support of FDA panel, July 30, 2026
- CURE: FDA Advisory Committee Backs RP1 for Advanced Melanoma, August 1, 2026
- PharmExec: FDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study, July 31, 2026
- BioSpace: Capricor CEO won’t rule out legal action against FDA after negative adcomm, July 31, 2026
Editorial Disclosure
This article is based entirely on publicly available information including company press releases, FDA advisory committee outcomes, and contemporaneous news coverage. Securities discussed include BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT), Replimune Group, Inc. (Nasdaq: REPL), and Capricor Therapeutics, Inc. (Nasdaq: CAPR). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. BriaCell’s Bria-PROS+: FDA clearance of an Investigational New Drug application (a Study May Proceed letter) permits the company to begin a Phase 1/2a clinical study; it is not an efficacy finding and does not indicate or guarantee eventual approval. No human clinical data exists yet for Bria-PROS+; cited preclinical data (AACR poster) has not been independently peer-reviewed by aktiego.com. Bria-IMT remains an investigational Phase 3 candidate and has not been approved by the FDA. The $2 million NCI grant referenced is non-dilutive funding specific to Bria-PROS+ manufacturing and clinical evaluation. Replimune’s RP1: the July 30, 2026 advisory committee vote (10 to 3) is non-binding. The FDA is not required to follow advisory committee recommendations and has diverged from them in prior cases involving single-arm study design concerns, which were the central objection raised by FDA staff ahead of this meeting. RP1 has received two prior Complete Response Letters (July 2025 and April 2026) and remains investigational, not approved by the FDA for any indication, as of this writing. Capricor’s deramiocel: CEO comments regarding potential legal action against the FDA are stated intentions, not filed legal action, as of this writing. The dispute concerns which version of a statistical analysis plan (SAP 1.1 draft versus SAP 3.0 final) should govern interpretation of Phase 3 HOPE-3 trial results; aktiego.com presents both Capricor’s and the FDA’s stated positions without endorsing either. The Lancet publication figures cited are as reported by Capricor’s own press release. Named analyst commentary (Oppenheimer) is hyperlinked to its original source via BioSpace’s reporting. Deramiocel remains investigational and has not been approved by the FDA for any indication; a second Complete Response Letter by the August 22 PDUFA date remains a credible outcome. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER
